Galectin Therapeutics, Inc. (GALT) Reaches $3.81 After 9.00% Down Move; Usana Health Sciences (USNA) Sellers Decreased By 11.23% Their Shorts

February 15, 2018 - By Nellie Frank

Usana Health Sciences Incorporated (NYSE:USNA) had a decrease of 11.23% in short interest. USNA’s SI was 889,800 shares in February as released by FINRA. Its down 11.23% from 1.00 million shares previously. With 132,700 avg volume, 7 days are for Usana Health Sciences Incorporated (NYSE:USNA)’s short sellers to cover USNA’s short positions. The SI to Usana Health Sciences Incorporated’s float is 8.96%. The stock increased 0.99% or $0.75 during the last trading session, reaching $76.5. About 41,450 shares traded. USANA Health Sciences, Inc. (NYSE:USNA) has risen 6.87% since February 15, 2017 and is uptrending. It has underperformed by 9.83% the S&P500.

The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) is a huge mover today! The stock decreased 3.30% or $0.13 during the last trading session, reaching $3.81. About 135,420 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 62.09% since February 15, 2017 and is uptrending. It has outperformed by 45.39% the S&P500.The move comes after 8 months negative chart setup for the $137.69 million company. It was reported on Feb, 15 by Barchart.com. We have $3.47 PT which if reached, will make NASDAQ:GALT worth $12.39M less.

Among 3 analysts covering USANA Health Science (NYSE:USNA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. USANA Health Science had 10 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has “Buy” rating by DA Davidson on Wednesday, September 16. Pivotal Research maintained USANA Health Sciences, Inc. (NYSE:USNA) on Wednesday, February 8 with “Buy” rating. Pivotal Research upgraded USANA Health Sciences, Inc. (NYSE:USNA) on Wednesday, August 5 to “Hold” rating. Pivotal Research downgraded USANA Health Sciences, Inc. (NYSE:USNA) on Monday, May 1 to “Hold” rating. Pivotal Research maintained USANA Health Sciences, Inc. (NYSE:USNA) on Wednesday, October 25 with “Buy” rating. The firm has “Neutral” rating given on Wednesday, January 24 by Sidoti. The stock has “Buy” rating by Sidoti on Friday, October 16. DA Davidson downgraded the shares of USNA in report on Thursday, August 6 to “Neutral” rating.

Investors sentiment decreased to 1.25 in 2017 Q3. Its down 0.22, from 1.47 in 2017Q2. It dived, as 22 investors sold USANA Health Sciences, Inc. shares while 37 reduced holdings. 30 funds opened positions while 44 raised stakes. 10.23 million shares or 3.93% less from 10.64 million shares in 2017Q2 were reported. Northern Trust invested in 177,137 shares. Next Grp has invested 0.02% in USANA Health Sciences, Inc. (NYSE:USNA). Lucus Advsrs Limited owns 6,038 shares for 0.49% of their portfolio. Martingale Asset Mngmt L P has 37,515 shares. Gsa Cap Ptnrs Ltd Liability Partnership stated it has 10,843 shares. Ellington Mgmt Ltd Com, Connecticut-based fund reported 5,700 shares. Rhumbline Advisers stated it has 0% of its portfolio in USANA Health Sciences, Inc. (NYSE:USNA). Pub Employees Retirement Sys Of Ohio has invested 0% in USANA Health Sciences, Inc. (NYSE:USNA). Schwab Charles Invest Mgmt, California-based fund reported 84,857 shares. Point72 Asia (Hong Kong) Ltd has invested 0.01% in USANA Health Sciences, Inc. (NYSE:USNA). Old Mutual Global Invsts (Uk) holds 0.14% of its portfolio in USANA Health Sciences, Inc. (NYSE:USNA) for 239,151 shares. Strs Ohio reported 0% of its portfolio in USANA Health Sciences, Inc. (NYSE:USNA). Cornerstone Capital Mgmt Ltd Liability Corporation stated it has 0.01% in USANA Health Sciences, Inc. (NYSE:USNA). Barclays Public Limited Company invested in 0% or 6,621 shares. Fort L P holds 715 shares.

Since August 21, 2017, it had 0 buys, and 17 sales for $43.01 million activity. WENTZ MYRON W had sold 79,294 shares worth $4.57 million on Tuesday, September 12. Gull Global Ltd had sold 38,223 shares worth $2.73M on Friday, February 2. Brown Jim also sold $975,256 worth of USANA Health Sciences, Inc. (NYSE:USNA) on Monday, August 21. Macuga Daniel A. also sold $345,060 worth of USANA Health Sciences, Inc. (NYSE:USNA) on Friday, August 25. 29,934 USANA Health Sciences, Inc. (NYSE:USNA) shares with value of $1.77 million were sold by Guest Kevin. 1,710 shares were sold by FULLER GILBERT A, worth $114,590. The insider Bramble James sold 18,298 shares worth $1.04 million.

USANA Health Sciences, Inc. develops, makes, and sells science nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company has market cap of $1.84 billion. The firm offers USANA Nutritionals Essentials product line, which includes vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It has a 21.13 P/E ratio. It also provides Sensé—beautiful science products, such as personal care products that support healthy skin and hair through topical nourishment, moisturization, and protection; and other products for prenatal, infant, and young child age groups.

Since January 25, 2018, it had 2 insider buys, and 2 sales for $2.64 million activity. CZIRR JAMES C sold $1.33 million worth of stock or 244,444 shares. FREEMAN KEVIN D had bought 2,000 shares worth $8,191 on Thursday, February 1. 10X Fund – L.P. sold 244,444 shares worth $1.33M.

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. On Thursday, March 30 the stock rating was upgraded by H.C. Wainwright to “Buy”. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) has “Buy” rating given on Monday, September 21 by H.C. Wainwright. The rating was downgraded by Roth Capital to “Sell” on Wednesday, September 28. The rating was downgraded by FBR Capital to “Mkt Perform” on Monday, October 3. Roth Capital maintained it with “Buy” rating and $8.0 target in Thursday, January 4 report. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, June 14. The rating was reinitiated by H.C. Wainwright with “Buy” on Monday, March 28. Roth Capital maintained Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Thursday, December 7. Roth Capital has “Buy” rating and $3.0 target. As per Thursday, September 29, the company rating was downgraded by H.C. Wainwright. TH Capital downgraded the shares of GALT in report on Wednesday, September 28 to “Sell” rating.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $137.69 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Investors sentiment decreased to 0.67 in 2017 Q3. Its down 1.22, from 1.89 in 2017Q2. It dropped, as 7 investors sold Galectin Therapeutics, Inc. shares while 8 reduced holdings. 4 funds opened positions while 6 raised stakes. 3.22 million shares or 4.39% less from 3.37 million shares in 2017Q2 were reported. Rathbone Brothers Public Limited Com accumulated 16,400 shares. Benchmark Advsr holds 194,200 shares or 0.32% of its portfolio. Buckingham Asset Management Ltd Liability has invested 0.03% in Galectin Therapeutics, Inc. (NASDAQ:GALT). First Republic Investment Management owns 26,000 shares for 0% of their portfolio. Susquehanna Group Ltd Liability Partnership owns 168,648 shares for 0% of their portfolio. Thrivent For Lutherans holds 6,000 shares or 0% of its portfolio. Us Fincl Bank De holds 0% or 118,921 shares. Dynamic Advsrs Solutions Llc reported 0.01% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Group One Trading Ltd Partnership holds 0% or 23,052 shares. Wells Fargo & Mn, California-based fund reported 11,882 shares. Retail Bank Of Mellon Corporation has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). New York-based Neuberger Berman Group Incorporated Ltd Liability Company has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). The California-based Schwab Charles Inv Mngmt has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Da Davidson And Company holds 690,960 shares. Norris Perne & French Llp Mi invested in 30,500 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Nellie Frank

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: